Explore the exciting world of BridgeBio Pharma(NASDAQ: BBIO) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and ...

BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports ...

BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq ...

Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a report issued on Monday, February 24th. Leerink Partnrs analyst M.

BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...

Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...